2024
Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1)
King B, Senna M, Mesinkovska N, Lynde C, Zirwas M, Maari C, Prajapati V, Sapra S, Brzewski P, Osman L, Hanna S, Wiseman M, Hamilton C, Cassella J. Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1). Journal Of The American Academy Of Dermatology 2024 PMID: 39053611, DOI: 10.1016/j.jaad.2024.06.097.Peer-Reviewed Original ResearchSeverity of Alopecia ToolAlopecia areataPrimary endpointHair regrowthTreatment-emergent adverse eventsOral JAK inhibitorsPlacebo-controlled trialLonger-term safetyProportion of patientsPercentage of patientsJanus kinase inhibitorsJanus kinasePatient-reported outcomesHair loss disorderImpact quality of lifeDouble-blindSecondary endpointsTreatment cessationAdult patientsAdverse eventsKinase inhibitorsJAK inhibitorsControlled trialsQuality of lifePatients
2021
27030 Extended safety analysis of baricitinib 2-mg in adult patients with atopic dermatitis: An integrated analysis from 8 randomized clinical trials
King B, Maari C, Lain E, Silverberg J, Issa M, Holzwarth K, Brinker D, Cardillo T, Nunes F, Simpson E. 27030 Extended safety analysis of baricitinib 2-mg in adult patients with atopic dermatitis: An integrated analysis from 8 randomized clinical trials. Journal Of The American Academy Of Dermatology 2021, 85: ab127. DOI: 10.1016/j.jaad.2021.06.525.Peer-Reviewed Original Research